APP and amyloidosis: Our results demonstrate that abnormal upregulation of FT occurs in the early stage of human AD, and suppressing neuronal FT alone confers neuroprotective benefits against cognitive deficits and amyloid pathology through reversing pathogenic hyperactivation of mTORC1 signaling in APP/PS1 mice (Fig. 11).